[go: up one dir, main page]

AR102926A1 - Composiciones anticancerosas - Google Patents

Composiciones anticancerosas

Info

Publication number
AR102926A1
AR102926A1 ARP150103982A ARP150103982A AR102926A1 AR 102926 A1 AR102926 A1 AR 102926A1 AR P150103982 A ARP150103982 A AR P150103982A AR P150103982 A ARP150103982 A AR P150103982A AR 102926 A1 AR102926 A1 AR 102926A1
Authority
AR
Argentina
Prior art keywords
solid dispersion
hpmcas
pharmaceutical formulation
rna
target compositions
Prior art date
Application number
ARP150103982A
Other languages
English (en)
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR102926(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of AR102926A1 publication Critical patent/AR102926A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Una dispersión sólida que comprende ARN-509 y HPMCAS. Reivindicación 10: Una partícula que consiste en una dispersión sólida tal como se define en cualquiera de las reivindicaciones anteriores. Reivindicación 12: Una formulación farmacéutica que comprende un vehículo farmacéuticamente aceptable y una dispersión sólida de acuerdo con cualquiera de las reivindicaciones 1 a 9. Reivindicación 16: Un proceso para preparar la dispersión sólida de acuerdo con la reivindicación 8 que comprende las etapas de mezclar ARN-509 y HPMCAS en un disolvente adecuado y someter dicha mezcla a deshidratación por aspersión. Reivindicación 19: El uso de la formulación farmacéutica de acuerdo con cualquiera de las reivindicaciones 12 a 15 para la preparación de un medicamento para el tratamiento del cáncer de próstata.
ARP150103982A 2014-12-05 2015-12-04 Composiciones anticancerosas AR102926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196594 2014-12-05

Publications (1)

Publication Number Publication Date
AR102926A1 true AR102926A1 (es) 2017-04-05

Family

ID=52006906

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103982A AR102926A1 (es) 2014-12-05 2015-12-04 Composiciones anticancerosas

Country Status (29)

Country Link
US (3) US20170360754A1 (es)
EP (2) EP4494636A3 (es)
JP (2) JP6937692B2 (es)
KR (2) KR102348320B1 (es)
CN (2) CN114886852A (es)
AR (1) AR102926A1 (es)
AU (3) AU2015358490B2 (es)
BR (1) BR112017011788A2 (es)
CA (1) CA2969656A1 (es)
CL (1) CL2017001371A1 (es)
CO (1) CO2017005572A2 (es)
CR (1) CR20170216A (es)
EA (1) EA201791222A1 (es)
ES (1) ES2996833T3 (es)
HR (1) HRP20241719T1 (es)
HU (1) HUE069689T2 (es)
IL (2) IL252323B (es)
MA (1) MA41107B1 (es)
MD (1) MD3226841T2 (es)
MX (2) MX387933B (es)
NZ (1) NZ770528A (es)
PH (1) PH12017500964A1 (es)
PL (1) PL3226841T3 (es)
RS (1) RS66323B1 (es)
SG (1) SG11201704267VA (es)
SM (1) SMT202400518T1 (es)
TW (2) TWI754258B (es)
UA (1) UA120950C2 (es)
WO (1) WO2016090098A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013323861C1 (en) 2012-09-26 2024-05-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
TWI709403B (zh) 2014-12-05 2020-11-11 美商艾瑞岡醫藥公司 抗癌症組成物（二）
PL3226841T3 (pl) * 2014-12-05 2025-03-03 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素
WO2020144650A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of prostate cancer
AU2020215176B2 (en) 2019-01-30 2025-02-27 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
AU2020215177A1 (en) 2019-01-30 2021-08-12 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
CA3160121A1 (en) 2019-11-04 2021-05-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023122842A1 (es) * 2021-12-31 2023-07-06 Gador Limitada Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
CN116183787A (zh) * 2022-12-26 2023-05-30 郑州德迈药业有限公司 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法
AU2024236119A1 (en) 2023-03-16 2025-09-25 Bayer Consumer Care Ag Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020097A1 (en) 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
AU2001232348A1 (en) 2000-02-21 2001-08-27 Takeda Chemical Industries Ltd. Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
EP1368001B1 (en) 2001-02-27 2005-10-26 AstraZeneca AB Pharmaceutical formulation comprising bicalutamide
EE200300476A (et) 2001-04-02 2003-12-15 Astrazeneca Ab 4-tsüanotrifluoro-3-(4-fluorofenüülsulfonüül)-2-hüdroksü-2-metüülpropiono-m-toluidii di ja PVP-d sisaldav tahke farmatseutiline kompositsioon
ATE480226T1 (de) * 2001-06-22 2010-09-15 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
CA2474958A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
WO2003077827A1 (en) 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
AU2003292509B2 (en) 2003-12-15 2007-08-02 Council Of Scientific And Industrial Research Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
GB0502790D0 (en) 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
KR101782236B1 (ko) 2005-05-13 2017-09-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
SI2656841T1 (sl) * 2006-03-27 2016-11-30 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljanje raka prostate in bolezni, povezanih z androgenimi receptorji
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
LT3124481T (lt) 2010-02-16 2018-06-11 Aragon Pharmaceuticals, Inc. Androgeno receptorių moduliatoriai ir jų panaudojimas
CN102525876B (zh) 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
EP2721003B1 (en) 2011-06-15 2018-01-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en) 2012-03-21 2015-02-05 Emphascience, Inc. Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
PL3533792T3 (pl) * 2012-06-07 2021-11-29 Aragon Pharmaceuticals, Inc. Postacie krystaliczne modulatora receptora androgenowego
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
BR112015002055A2 (pt) * 2012-08-24 2017-07-04 Dow Global Technologies Llc acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence
CN105358535B (zh) 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
AU2013323861C1 (en) * 2012-09-26 2024-05-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
HK1211217A1 (en) 2013-01-22 2016-05-20 霍夫曼-拉罗奇有限公司 Pharmaceutical composition with improved bioavailability
KR102121404B1 (ko) 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
US9808472B2 (en) * 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EA037895B1 (ru) * 2014-02-05 2021-06-02 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
KR102348325B1 (ko) 2014-12-05 2022-01-06 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
TWI709403B (zh) 2014-12-05 2020-11-11 美商艾瑞岡醫藥公司 抗癌症組成物（二）
PL3226841T3 (pl) 2014-12-05 2025-03-03 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
UA124154C2 (uk) 2016-06-03 2021-07-28 Арагон Фармасьютікалз, Інк. Протиракові композиції
KR20210023987A (ko) 2018-06-20 2021-03-04 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. Arn-509의 결정형, 그 제조방법 및 그 용도
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide

Also Published As

Publication number Publication date
CN114886852A (zh) 2022-08-12
EA201791222A1 (ru) 2017-09-29
MA41107A (fr) 2017-10-10
TW201630592A (zh) 2016-09-01
CN106999431A (zh) 2017-08-01
TWI702966B (zh) 2020-09-01
US20170360754A1 (en) 2017-12-21
HRP20241719T1 (hr) 2025-02-14
JP2020143069A (ja) 2020-09-10
US12303493B2 (en) 2025-05-20
CN106999431B (zh) 2022-03-04
NZ731963A (en) 2024-03-22
CO2017005572A2 (es) 2017-09-20
JP6937692B2 (ja) 2021-09-22
KR102348320B1 (ko) 2022-01-10
SG11201704267VA (en) 2017-06-29
ES2996833T3 (en) 2025-02-13
IL279833B (en) 2022-03-01
IL252323A0 (en) 2017-07-31
TW202031248A (zh) 2020-09-01
MA41107B1 (fr) 2025-01-31
MX387933B (es) 2025-03-19
EP3226841C0 (en) 2024-10-09
TWI754258B (zh) 2022-02-01
RS66323B1 (sr) 2025-01-31
EP4494636A2 (en) 2025-01-22
EP3226841A1 (en) 2017-10-11
AU2015358490B2 (en) 2021-04-08
KR20200141533A (ko) 2020-12-18
MX2017007203A (es) 2017-08-28
IL279833A (en) 2021-01-31
EP3226841B1 (en) 2024-10-09
SMT202400518T1 (it) 2025-01-14
JP2017536398A (ja) 2017-12-07
MX2021013965A (es) 2022-01-04
AU2021201979B2 (en) 2023-02-02
AU2015358490A1 (en) 2017-06-08
CL2017001371A1 (es) 2018-01-05
CR20170216A (es) 2017-08-30
BR112017011788A2 (pt) 2017-12-26
UA120950C2 (uk) 2020-03-10
MD3226841T2 (ro) 2025-06-30
PH12017500964A1 (en) 2017-10-18
AU2021201979A1 (en) 2021-04-29
JP7174006B2 (ja) 2022-11-17
US20230233529A1 (en) 2023-07-27
IL252323B (en) 2021-04-29
US20240293374A1 (en) 2024-09-05
KR20170086656A (ko) 2017-07-26
NZ770528A (en) 2024-03-22
WO2016090098A1 (en) 2016-06-09
CA2969656A1 (en) 2016-06-09
PL3226841T3 (pl) 2025-03-03
EP4494636A3 (en) 2025-04-30
HUE069689T2 (hu) 2025-04-28
AU2023202710A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
AR102926A1 (es) Composiciones anticancerosas
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
MX377877B (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2015013247A (es) Formulacion de acetato de abiraterona.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
BR112018011929A2 (pt) composto, composição farmacêutica, métodos para tratamento da infecção viral da hepatite c, de carcinoma basocelular, de ceratose actínica, da infecção viral de papiloma genital e da infecção viral de hepatite c, processo para preparação de um composto, e, uso de um composto
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
PE20160930A1 (es) Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
WO2015033302A3 (en) Fulvestrant compositions
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
MX2016014826A (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
WO2014118808A3 (en) Ticagrelor solid dispersion
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
CL2015001459A1 (es) Nueva composición farmacéutica.

Legal Events

Date Code Title Description
FC Refusal